Augmenting the Benefit of Hormonal Therapy in Breast Cancer

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.

Clinical Pearls

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.

  • The CDK4/6 inhibitor palbociclib has yielded exciting preliminarily results
  • In a phase II study, the combination of palbociclib and letrozole tripled PFS compared with letrozole alone (26.1 months versus 7.5 months)
  • The HDAC inhibitor entinostat plus hormonal therapy was found to improve survival in a phase II study
  • Src inhibition showed benefit in a trial